Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AMED 
Amedisys Inc (AMED)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AMED (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $95.2
1 Year Target Price $95.2
| 0 | Strong Buy |
| 1 | Buy |
| 9 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.55% | Avg. Invested days 57 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.32B USD | Price to earnings Ratio 39.3 | 1Y Target Price 95.2 |
Price to earnings Ratio 39.3 | 1Y Target Price 95.2 | ||
Volume (30-day avg) 11 | Beta 0.9 | 52 Weeks Range 82.15 - 101.02 | Updated Date 08/28/2025 |
52 Weeks Range 82.15 - 101.02 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.56% | Operating Margin (TTM) 11.7% |
Management Effectiveness
Return on Assets (TTM) 6.52% | Return on Equity (TTM) 6.67% |
Valuation
Trailing PE 39.3 | Forward PE 22.03 | Enterprise Value 3434532125 | Price to Sales(TTM) 1.38 |
Enterprise Value 3434532125 | Price to Sales(TTM) 1.38 | ||
Enterprise Value to Revenue 1.43 | Enterprise Value to EBITDA 14.39 | Shares Outstanding 32887700 | Shares Floating 32237519 |
Shares Outstanding 32887700 | Shares Floating 32237519 | ||
Percent Insiders 1.95 | Percent Institutions 96.37 |
Upturn AI SWOT
Amedisys Inc
Company Overview
History and Background
Amedisys, Inc. was founded in 1982. Initially focused on home healthcare in Louisiana, it has grown through organic expansion and acquisitions to become a national provider of home health, hospice, and personal care services.
Core Business Areas
- Home Health: Provides skilled nursing, therapy, and other healthcare services to patients in their homes.
- Hospice: Offers palliative and end-of-life care services to patients with terminal illnesses.
- Personal Care: Provides assistance with daily living activities, such as bathing, dressing, and meal preparation.
Leadership and Structure
The leadership team consists of the CEO, CFO, COO, and other key executives. The organizational structure includes regional and local operating units, with centralized support functions.
Top Products and Market Share
Key Offerings
- Home Health Services: Skilled nursing, physical therapy, occupational therapy, speech therapy, and medical social services delivered in the patient's home. Competitors include LHC Group, Encompass Health, and AccentCare. Market share is difficult to pinpoint precisely but Amedisys is a top 3 player.
- Hospice Care: Comprehensive care for terminally ill patients, including pain management, emotional support, and spiritual care. Competitors include LHC Group, AccentCare, and VITAS Healthcare. Market share is difficult to pinpoint precisely but Amedisys is a top 3 player.
Market Dynamics
Industry Overview
The home health and hospice industry is growing due to the aging population, increasing prevalence of chronic diseases, and the shift towards value-based care. The industry is highly regulated and competitive.
Positioning
Amedisys is a leading provider of home health and hospice services, with a strong reputation for quality and a broad geographic footprint. The company differentiates itself through its integrated care model and focus on patient outcomes.
Total Addressable Market (TAM)
The TAM for home health and hospice care in the US is estimated to be over $100 billion. Amedisys is well-positioned to capture a significant share of this market through organic growth and acquisitions.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Large geographic footprint
- Integrated care model
- Experienced management team
- Scalable infrastructure
Weaknesses
- Exposure to regulatory changes
- Dependence on government reimbursement
- High employee turnover
- Potential for litigation
- Acquisition integration risks
Opportunities
- Growing demand for home health and hospice services
- Expansion into new geographic markets
- Development of new service lines
- Strategic acquisitions
- Partnerships with healthcare providers
Threats
- Increased competition
- Decreased reimbursement rates
- Regulatory scrutiny
- Economic downturn
- Labor shortages
Competitors and Market Share
Key Competitors
- LHCG
- EH
- HRHC
Competitive Landscape
Amedisys competes with other national and regional home health and hospice providers. The company's advantages include its strong brand reputation, large geographic footprint, and integrated care model. Disadvantages include its exposure to regulatory changes and dependence on government reimbursement.
Major Acquisitions
Contessa Health
- Year: 2021
- Acquisition Price (USD millions): 250
- Strategic Rationale: Expanded Amedisys' capabilities in hospital-at-home and high-acuity care.
Growth Trajectory and Initiatives
Historical Growth: Amedisys has grown significantly over the past decade through organic growth and acquisitions.
Future Projections: Analyst estimates project continued growth in revenue and earnings, driven by the aging population and increasing demand for home health and hospice services.
Recent Initiatives: Recent initiatives include expanding into new markets, developing new service lines, and investing in technology.
Summary
Amedisys is a major player in the growing home health and hospice industry, with a strong reputation and broad reach. Its dependence on government reimbursement and the presence of strong competitors are challenges to watch out for. Recent acquisitions have expanded its capabilities, and continued growth is anticipated.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Relations Materials
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amedisys Inc
Exchange NASDAQ | Headquaters Baton Rouge, LA, United States | ||
IPO Launch date 1994-08-17 | President, CEO & Director Mr. Richard M. Ashworth | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 19000 | Website https://www.amedisys.com |
Full time employees 19000 | Website https://www.amedisys.com | ||
Amedisys, Inc. provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment provides a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was formerly known as Analytical Nursing Management Corp. and changed its name to Amedisys, Inc. in August 1995. The company was founded in 1982 and is headquartered in Baton Rouge, Louisiana with an additional office in Nashville, Tennessee. As of August 14, 2025, Amedisys, Inc. operates as a subsidiary of Optum, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.